Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma Read more
Analysis of stem cell products immunological parameters and recipient outcome in autologous and allogeneic peripheral blood stem cell transplantation Read more
A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA Read more
This protocol is for the use of CliniMACS CD34 Reagent System in a single patient with relapsed AML. Patient received salvage chemo and planned stem cell boost for cytopenias. Since donor is a haplo, plan is to give CD34 selected cells with some t cell add back. Read more
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial Read more
Phase II Study of Nivolumab/Ipilimumab plus Cabozantinib in Patients with Unresectable Advanced Melanoma Read more
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Read more
A Phase 1, First-in-Human, Open- Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms? (the ?Study?). Read more
A Phase 1, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients with Locally Advanced or Metastatic Solid Tumors Read more
